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Introduction
 Radiotherapy is often the treatment of choice for 
malignant tumors in the head and neck region 
because it ensures the maintenance of function 
and morphology.  However, when a salivary gland 
is included in the radiation ﬁeld, there is an 
increased risk of abnormalities in the oral cavity 
function, such as xerostomia, eating disorders, 
mastication/deglutination disorders, increased 
rate of infection, and frequent occurrence of dental 
caries1,2.  Therefore, a decrease of salivary gland 
disorders is warranted in cases of radiotherapy to 
this region.
 Amifostine3, which was screened in the 1980s, 
shows lower toxicity than the previously used 
aminothiol substances and is quickly absorbed by 
healthy tissues.  Furthermore, gradual absorption 
of amifostine by poorly vascularized tumors limits 
its protective effect on tumors.  In the USA, ami-
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Abstract : To investigate the effect of amifostine, we administered amifostine, a radioprotective 
agent, 30 minutes before exposing the maxillary region of mice, including the parotid gland, to 5 
Gy or 10 Gy X-ray irradiation.  The survival rate was recorded, and changes in the parotid gland 
morphology were investigated by examining the hematoxylin and eosin (HE)-stained specimens 
and light microscope autoradiography (LMARG) images obtained 30 days after irradiation.  A sur-
vival rate of 100% was not observed in any group administered 200 mg/kg amifostine with or with-
out irradiation.  Among the groups irradiated with 10 Gy X-rays, the survival rate was higher and 
the survival period was longer in the 100 mg/kg amifostine group than in the no amifostine group.  
The histological ﬁndings in the group that received 5 Gy irradiation without amifostine were as fol-
lows : auxetic growth of acinar cells, nuclei of all sizes, cells in the mitotic phase, and cells undergo-
ing apoptosis. Further, the treated groups were compared with the no amifostine and no irradiation 
group (untreated control).  LMRG imaging revealed that the number of reduced silver grains per 
mm2 of acinar cells after 30 min of 3H-leucine administration was higher than that after 120 min in 
mice treated with 100 mg/kg amifostine with or without 5 Gy irradiation.  This observation was 
similar to that in the untreated control.
 This ﬁnding suggests that although amifostine administration reduces the adverse effects of ir-
radiation on the parotid gland, higher doses of amifostine may be fatal.
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fostine has been widely used in radiotherapy to 
the head and neck region4,5.  However, some 
reports have indicated its side effects such as nau-
sea, emesis, and induction of hypotension or 
hypocalcemia6,7.  Thus, its optimal dose and 
administration period remain to be established. 
Further, several animal studies8,9 have measured 
only the quantity and constituents of the saliva 
secreted from irradiated salivary glands.  Consid-
ering all these aspects, in this study, we his-
tochemically investigated the effect of different 
doses of amifostine on the parotid gland and the 
relationship between amifostine administration 
and radiation damage.
Materials and Methods
1. Experimental Animals and Breeding Con-
ditions
 Eight-week-old Balb/c male mice weighing 
approximately 30 g (Tokyo Laboratory Animals 
Science Co. Ltd., Japan) were used as experimen-
tal animals.  For the adaptation of the animals to 
the experimental set-up, the mice were main-
tained for one week at room temperature (25℃) 
under a 12-h light-dark cycle.  Subsequently, the 
mice were randomly divided into 9 groups from A 
to K according to the doses of amifostine (0, 100, 
and 200 mg/kg) and irradiation (0, 5, and 10 Gy, 
Table 1) administered.  Each group included 4 
mice.  Throughout the experimental period, the 
mice were allowed unrestricted access to standard 
food and water ; however, at 12 h prior to amifos-
tine administration, the intake of only tap water 
was allowed.  The animals were handled and 
treated in accordance with the guidelines for 
experimental animals issued by the Nippon Den-
tal University School of Life Dentistry.
2. Administration of Amifostine
 Amifostine (WR2721, Ethyol ; Medimmune 
Oncology, Inc., Gaithersburg, MA, USA) was 
diluted using physiological saline solution. 
Intraabdominal injection of amifostine was 
administered 30 min prior to X-ray irradiation at 
a dose of 100 mg/kg into the mice of groups D, E, 
and F, and at a dose of 200 mg/kg into the mice of 
groups G, H, and K.  Physiological saline solution 
(dose, body weight (g) × 0.02 ml) was injected 
intraabdominally into the mice of groups A, B, and 
C.
3. X-ray Irradiation
 A Hitachi X-ray generator (MBR-1520R-3 ; 
Hitachi Medical Corporation, Japan) was used for 
X-ray irradiation, which was applied to the experi-
mental mice under general anesthesia with an 
intraabdominal injection of 10 ml/kg pentobarbital 
sodium (SomnopentilⓇ ; Schering-Plough Animal 
Health Corporation, USA).  The maxillary region, 
including the parotid gland, was irradiated ; the 
mice in groups B, E, and H received 5 Gy irradia-
tion, while those in groups C, F, and K received 10 
Gy irradiation under the following conditions : 
tube voltage, 20 mA; tube current, 20 mA; ﬁlter, 
1.0-mm Al ; and dosage rate, 2.1 Gy/min.
4. Survival Rate and Period
 The survival rate and period of the mice in each 
group were determined at 30 days after the irradi-
ation according to the procedure described by 
Pamujula et al.10.
5. Preparation of Histological Specimens
 Specimens of the parotid glands in groups A, B, 
D, and E were obtained 30 days after X-ray irradi-
ation.  These specimens were prepared for histo-
logical analysis as follows : After the mice were 
sacriﬁced by overdose of pentobarbital sodium, 
their parotid glands were enucleated and ﬁxed 
with 10% formalin neutral buffer solution for 24 h. 
The ﬁxed parotid glands were then dehydrated 
using an ethanol series and embedded in parafﬁn. 
The parafﬁn-embedded parotid glands were sliced 
to obtain approximately 4-μm-thick sections ; 
these sections were then stained with hematoxy-
Table 1　Classiﬁcation of the experimental groups
X-ray
Amifostine
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lin-eosin (HE) stain, and observed under a light 
microscope (Leica DMRE; Leica Microsystems 
GmbH, Germany).
6. Light Microscope Autoradiography (LMARG)
   After 30 days of irradiation, the mice in groups 
A, B, D, and E were administered an intraabdomi-
nal injection of 370 kBq/g of 3H-leucine (L-leucine-
4,5-3H, 2.22–3.33 TBq (60–90 Ci)/mmol ; Moravek 
Biochemicals, Inc., USA) (hereafter referred to as 
RI administration).  The mice in each of the 
abovementioned groups were sacriﬁced under 
deep anesthesia at 30 and 120 min after RI 
administration, because in LMARG, the reduced 
silver grains in the acinar cells of the parotid 
gland show a maximum value at 30 min after 
3H-leucine administration and thereafter 
decreases with time11.  The parotid glands were 
enucleated and their central portion was cut into 
ﬁne particles of approximately 1 mm3 in volume. 
These pieces were ﬁxed with 2.5% glutaric alde-
hyde for two hours and 1.0% osmic acid for one 
hour.  The embedded specimens in Epon-Araldite 
resin were thinly sliced to approximately 1-μm- 
thick sections.  The obtained sections were ﬁnally 
dipped in an emulsion for LMARG (NTB; East-
man Kodak Company, USA) so that silver grains 
formed a single layer on each section.  After expos-
ing the sections for one week, they were processed. 
To obtain images of the specimens, the ﬁxed sec-
tions were photographed under a confocal laser-
scanning microscope (NTB SP; Leica Microsys-
tems GmbH, Germany) in the differential 
interference mode.  The number of reduced silver 
grains on the image was counted and then con-
verted to a value indicating the number of grains 
per mm2 of acinar cells.  The values obtained at 30 
and 120 min after RI administration were com-
pared between group A and groups B, D, and E. 
Further, in order to examine the effect of amifos-
tine on the irradiated parotid glands, the values 
were compared between groups B and E.  In addi-
tion, the value obtained at 30 min after RI admin-
istration was compared with that obtained at 120 
min for each group.  The deviation from the aver-
age value was calculated using Welch’s t test.
Results
1. Survival Rate and Period in the Various 
Groups
 The survival rates and periods are shown in 
Table 2 ; the changes in survival rate are shown in 
Fig. 1.  Groups A, B, D, and E showed a survival 
rate of 100% at 30 days after X-ray irradiation. 
Group G, which received 200 mg/kg amifostine 
without X-ray irradiation, did not show a survival 
rate of 100%.  Among the groups receiving 10 Gy 
irradiation, the survival rate and period were 
higher in the group administered 100 mg/kg ami-
fostine (group F) than in the group not adminis-
tered amifostine (group C).  The survival rate and 
period were lower in the groups administered 200 
mg/kg amifostine (group K) than in the group 
administered 100 mg/kg amifostine.
2. Morphological Changes in the Acinar Cells
 In group A, the terminal portion cells along with 
a few adhered conical cells formed the acinar.  The 
nucleus was circular or semicircular and located 
basally (Fig. 2a).  In contrast to group A, group B 
showed auxetic growth of acinar cells, nuclei of all 
sizes, cells in the mitotic phase (indicated by 
arrows), and cells undergoing apoptosis (top left) 
(Fig. 2b).  Although group D showed a slightly 
irregular arrangement of the acinar cells, the cell 
morphology in this group was almost identical to 
that in group A (Fig. 2c).  Further, although a 
slight auxetic growth of acinar cells and nuclei of 
all sizes were observed in group E, the variations 
in group E were less than those in group B, and 
the histopathological image of group E was similar 
to those of groups A and D (Fig. 2d).
3. Number of Reduced Silver Grains in Aci-
nar Cells on LMARG Images
 The LMARG images of groups A, B, D, and E at 
30 and 120 min after RI administration are shown 
in Fig. 3.  The number of reduced silver grains per 
mm2 of acinar cells for each group is listed in 
Table 3 and Fig. 4.  The number obtained at 30 
min after RI administration was signiﬁcantly 
higher in group A than in group B.  In groups A 
and D, the values obtained at 30 min after RI 
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administration were higher than those obtained at 
120 min.  A similar tendency was observed in 
group E.  In contrast, in group B, the value 
obtained at 120 min after RI administration was 
signiﬁcantly higher than that obtained at 30 min.
Discussion
 Under the action of alkaline phosphatase, ami-
fostine acts as a phosphoric acid-type prodrug and 
binds to the SH group to transform to a new type 
of prodrug (WR-1065) containing an active SH 
group12.  This new prodrug has a protective effect 
and low toxicity.  Since healthy tissues have sufﬁ-
cient blood supply, they beneﬁt the most from such 
drugs because of the rapid absorption of these 
drugs by the blood.  Conversely, the protective 
effect of such drugs on tumors is considered to be 
less because tumors have poor vasculature and 






(days ± SE) 
A,B,D,E 100 ＞ 30 
G  75 28.8± 2.5 
H 　0  8.3± 3.0 
C  25 16.0± 3.9 
F  50 26.5± 2.8 
K  25 11.0± 5.5 
Fig. 1　Changes in the survival rate in each group
Fig. 2 a : HE-stained image of group A, b : HE-stained image of group B,  
c : HE-stained image of group D, d : HE-stained image of group E  (Bar : 10 μm)
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therefore inadequate drug absorption.  Further-
more, salivary glands, etc.  have been reported to 
absorb high concentrations of drugs13.  In the 
USA, amifostine has been used clinically to pro-
tect healthy salivary glands during radiotherapy 
to the head and neck region4,5.  However, side 
effects of amifostine, such as nausea, emesis, and 
tendency of hypotension and hypocalcemia, have 
been reported6,7.  Therefore, the optimal dose and 
administration period of amifostine remain to be 
determined for its clinical application.  Inadequate 
data on amifostine has hindered its effective use 
Fig. 3 LMARG images of each group at 30 min and 120 min after RI administration 
(Bar : 10 μm)
a: group A, 30 min, b : group A, 120 min, c : group B, 30 min, d : group B, 120 min,
e : group D, 30 min, f : group D, 120 min, g : group E, 30 min, h : group E, 120 min
Table 3　Number of reduced silver grains per mm2 of acinar cells
Group A B D E 
Time after RI administration (min.) 30 120 30 120 30 120 30 120
Average value 12.5 11.1 5.1 11.8 11.8 9.7 10.2 7.0
SD 1.3 1.3 1.0 2.1 1.5 2.6 1.3 1.7
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in clinical settings.
1. Methods
 There exist numerous reports on various irradi-
ation conditions, including the type, intensity, and 
region of irradiation, applied in mice experiments. 
Some of the irradiation conditions studied are as 
follows : 7.5–12.5 Gy X-ray irradiation locally14, 15 
Gy X-ray irradiation to the whole body15, and 60Co 
γ-ray irradiation at a dose of 6 Gy locally16.  In 
this study, the doses of X-ray irradiation were set 
at 5 Gy and 10 Gy on the basis of the survival 
results obtained in a preparatory experiment. 
Previous reports indicated that amifostine has 
been administered at doses of 400 mg/kg17, 200 
mg/kg14, and 100 mg/kg18 to the Rodentia family 
(mainly the mouse and rat).  Damron et al.19 stud-
ied the effect of amifostine in the dose range of 
0–250 mg/kg.  They found that amifostine exhib-
ited its radioprotective effect at doses above 100 
mg/kg and that its toxicity increased at doses 
above 200 mg/kg.  On the basis of these ﬁndings, 
amifostine doses of 100 mg/kg and 200 mg/kg were 
selected for the current experiment.  The most 
effective timing of amifostine administration has 
been reported to be 15 min20, 15–30 min17, 20–30 
min10, 25 min21, and 60 min10 prior to radiation 
therapy.  Since the effective administration timing 
ranged between 15 and 60 min before irradiation 
in all these studies, we administered amifostine at 
30 min before irradiation.  The observation time 
selected for this experiment was 30 days after 
X-ray irradiation.  Coppes et al.22 irradiated the 
neck region of mice with 15 Gy X-rays, and 
observed the consequent changes in the mice over 
a 240-day period that was divided into 4 subperi-
ods of 60 days each ; decreases in the number of 
acinar cells and amylase secretion were then 
observed over a period of 10–60 days.  In the 
report by Pamujula et al.10 wherein the effects of 
whole-body irradiation with 9 Gy 137Cs γ-rays was 
observed over a 30-day period, the effect of amifos-
tine was found to be greater a few days after 
administration than immediately after adminis-
tration.  A survival rate of 50% at 30 days after 
exposure of an animal group (LD50/30 (lethal 
damage dose 50%, 30 days)) has been used as one 
of the criteria for investigating the optimal dose of 
medication, reaction to medication, and inﬂuence 
of irradiation.  Hence, in the present study, 30 
days after irradiation was selected as the observa-
tion period.
2. Survival Period and Rate
 The relationship between amifostine adminis-
tration and the effects of whole-body irradiation 
were investigated by analyzing the survival rate 
and period.  A 100% survival rate at 30 days after 
irradiation was observed in groups A, B, D, and E. 
The dose of 100 mg/kg amifostine is considered as 
an appropriate dose for reducing radiation injuries 
because among the groups irradiated with 10 Gy 
X-rays, the group administered 100 mg/kg amifos-
tine (group F) exhibited a better survival rate and 
period than the group administered no amifostine 
(group C).  In contrast, the groups administered 
200 mg/kg amifostine had worse survival rates 
and periods.  Although the underlying mechanism 
is not known, it is considered that amifostine and 
radiation have contrasting but synergistic effects 
Fig. 4 Number of reduced silver grains per mm2 of acinar cells at 30 min and 
120 min after RI administration
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on a living body.  Since a 100% survival rate could 
not be achieved in group G, we consider that in 
mice, the intraabdominal injection dose of amifos-
tine should be less than 200 mg/kg.  Furthermore, 
Damron et al.19 and Yuhas et al.23 reported that 
doses greater than 200 mg/kg amifostine were 
fatal ; this result was validated in the present 
study.
3. Morphology of Acinar Cells
 Since slight morphological changes were 
observed in group D, the inﬂuence of amifostine 
on morphology is conﬁrmed.  Among the groups 
irradiated with 5 Gy X-rays, morphological 
changes were greater in the group administered 
no amifostine (group B) than in the group admin-
istered 100 mg/kg amifostine (group E).  This con-
ﬁrmed that the administration of 100 mg/kg ami-
fostine prior to irradiation was effective in 
reducing the radiation-induced morphological 
changes.  Cameron24 reported that the survival 
period of acinar cells in the mouse submandibular 
gland was 185 days, while that of exocrine cells of 
the mouse pancreas was 520 days ; therefore, the 
cells were considered to require a long turnover 
time.  In the present study, the cells in the mitotic 
phase and apoptosis-like cells were not observed 
in the tissue images of group D25.  However, these 
cell types were observed in many tissue images of 
group B.  This is considered to reﬂect the phenom-
enon wherein irradiation induces apoptosis26 and 
the number of acinar cells decreases at 30 days 
after irradiation17.
4. Leucine Quantity in Acinar Cells
 Onodera et al.11 sequentially observed the leu-
cine absorption ability of the acinar cells of the 
mouse parotid gland by using LMARG.  The 
amount of leucine in the acinar cells of the parotid 
gland was highest at 30 min after RI administra-
tion (3H-leucine was injected intraabdominally 
into the mice).  Thereafter, leucine was mainly 
excreted from the cells in the form of secretion 
granules, and the amount secreted decreased with 
time.  This study clariﬁed that amino acid absorp-
tion and excretion were slower in the irradiation 
groups than in the non-irradiation groups ; this is 
because irradiation causes abnormalities in the 
transport system of the cell membrane and intrac-
ellular metabolic system of the acinar cells of the 
parotid glands.  This study also clariﬁed that ami-
fostine relieves the irradiation-induced functional 
disorder of the acinar cells since amifostine inhib-
ited the action of free water radicals that absorb 
radiation energy and molecules that compose the 
cells.  Appropriate administration of amifostine 
not only reduces the harmful effects of irradiation 
but also alleviates acute heart toxicity (heart fail-
ure symptoms such as cardiac muscle softening, 
palpitation, and breathlessness) induced by adri-
amycin, which is an anticancer agent28.  As 
expected, fundamental data from various ﬁelds 
are required to establish the optimum conditions 
for amifostine administration.  Thus, amifostine 
has a potential role in future cancer therapy.
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